Q-omics provides the consensus-scored MBOAT2 profile across patient tissues and cancer cell-line models. MBOAT2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MBOAT2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MBOAT2 RNA expression shows 19,661 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where MBOAT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MBOAT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MBOAT2 survival associations across molecular data types. MBOAT2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MBOAT2 RNA expression–survival associations across cancer types. High MBOAT2 expression shows unfavorable associations in MESO, ACC, UVM, BLCA, UCEC and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MBOAT2 RNA expression.
This table summarizes MBOAT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MBOAT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MBOAT2 shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD, THCA, BLCA and BRCA. The KIRC box plot shows higher MBOAT2 RNA expression in normal versus tumor tissue (log2 FC = −1.654, t-test p < 0.001).
This table shows molecular features associated with MBOAT2 in patient tissues and cancer cell lines. In patient samples, MBOAT2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MBOAT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
